



ISSN: 2348-5906  
CODEN: IJMRK2  
IJMR 2022; 9(6): 107-115  
© 2022 IJMR  
[www.dipterajournal.com](http://www.dipterajournal.com)  
Received: 09-08-2022  
Accepted: 11-09-2022

**Narayan Lal Choudhary**  
Research Scholar  
Wildlife Limnology and  
Toxicology Research  
Laboratory, Department of  
Zoology, Government Meera  
Girls College (MLSU), Udaipur,  
Rajasthan, India

**Pushkar Kumawat**  
Research Scholar  
Wildlife Limnology and  
Toxicology Research  
Laboratory, Department of  
Zoology, Government Meera  
Girls College (MLSU), Udaipur,  
Rajasthan, India

**Pritesh Patel**  
Research Scholar  
Wildlife Limnology and  
Toxicology Research  
Laboratory, Department of  
Zoology, Government Meera  
Girls College (MLSU), Udaipur,  
Rajasthan, India

**Nadim Chishty**  
Associate Professor, Department  
of Zoology, Wildlife Limnology  
and Toxicology Research  
Laboratory, Government Meera  
Girls College (MLSU), Udaipur,  
Rajasthan, India

**Corresponding Author:**  
**Nadim Chishty**  
Associate Professor, Department  
of Zoology, Wildlife Limnology  
and Toxicology Research  
Laboratory, Government Meera  
Girls College (MLSU), Udaipur,  
Rajasthan, India

## Dengue and natural remedies for its prevention and control: A review

**Narayan Lal Choudhary, Pushkar Kumawat, Pritesh Patel and Nadim Chishty**

DOI: <https://doi.org/10.22271/23487941.2022.v9.i6b.646>

### Abstract

Dengue virus is the most common mosquito borne viral infection and is caused by four different serotypes of dengue virus, named DENV-1, DENV-2, DENV-3 and DENV-4, which belongs to Flaviviridae family and *Flavivirus* genus. It is transmitted by the *Aedes* mosquito from one infected person to another healthy person. A frontal headache, retro-orbital pain, body aches, rashes, nausea, vomiting, weakness and a high body temperature are the main symptoms of dengue infection. Dengue haemorrhagic fever and dengue shock syndrome can result in death in severe cases if proper treatment is not given. Several medical technologies, such as monoclonal antibodies, tetravalent subunits, inactivated and live attenuated vaccines have been adopted globally, but developing and under developed countries cannot afford them due to high costs. Various developing countries use herbal and natural remedies to prevent and control dengue. In this review, we are discussing about various plant species that have antiviral, ovicidal, larvicidal and mosquito repellent properties as well as compound that can be used to treat dengue fever.

Following species of plants *Momordica charantia*, *Alternanthera philoxeroides*, *Andrographis paniculata*, *Cladosiphon okamuranus*, *Carica papaya*, *Momordica charantia*, *Andropogon citratus*, *Curcuma longa*, *Piper longum*, *Piper ribesoides*, *Piper sarmentosum*, *Eupatorium perfoliatum*, *Kaempferia parviflora*, *Solanum villosum*, *Azadirachta indica*, *Pongamia glabra*, *Eupatorium odoratum*, *Catharanthus roseus*, *Nyctanthes arbor-tristis*, *Acalypha alnifolia*, *Delonix elata*, *Ocimum sanctum*, *Tinospora rumphii*, *Citrus grandis*, *Jatropha curcas*, *Ageratum houstonianum*, *Albizia lebeck*, *Aristolochia bracteata*, *Houttuynia cordata*, *Hippophae rhamnoides*, *Kaempferia parviflora*, *Leucaena leucocephala*, *Mimosa scabrella*, *Piper sarmentosum*, *Psidium guajava*, *Rhizophora apiculata*, *Boesenbergia rotunda* and *Quercus lusitanica* are widely used for treatment and control of dengue. Plant products and herbal remedies provided alternative of medicine for cure and recovery of various diseases including dengue fever.

**Keywords:** Dengue, *Aedes*, natural remedies, plant, vaccine, symptoms

### Introduction

Dengue fever is most common mosquito-borne viral infection and has rapidly become a major global health problem [1]. Dengue fever is a viral disease that has highly influenced human health and caused adverse impacts on tropical and subtropical regions [2]. At present, four different types of dengue serotypes have been identified that are DENV-1, DENV-2, DENV-3 and DENV-4 and which belongs to the Flaviviridae family and *Flavivirus* genus [2, 3, 4]. It is spreaded by *Aedes* mosquitoes, primarily who breeds in urban habitats [2, 3, 4, 5]. According to WHO, dengue is widespread in over 100 nations including the Asia, Americas, Africa, Pacific and Caribbean regions. Dengue cases have sharply risen in worldwide and currently reached pandemic levels [6]. Approximately 2.5 billion peoples are supposed to be at risk of dengue infection and an estimated 50 million cases are reported annually [6]. Dengue disease is not only a burden on health care but also has a negative influence on the economy due to illness, premature death and rising healthcare expenses [7]. At present dengue fever occurs in both epidemic and scattered forms [2, 8]. Most dengue infections cause nonspecific symptoms such as body aches, nausea, vomiting, weakness, rash, retro-orbital pain and frontal headache [9, 10]. Several medical technologies have been used to combat DENV, including monoclonal

antibodies [11], tetravalent subunit vaccine [12], inactivated vaccine [13], DNA based vaccine [14] and live attenuated vaccine [15]. However, no licensed dengue vaccines or medications are currently available in the market. There are no effective preventative medications available and only supportive therapy is possible for dengue patients [1, 8]. Medicinal herbs are crucial as primary health care and are used by humans daily to treat a variety of diseases [16, 17]. Naturally obtained products have been identified as an essential alternative for treating a variety of infections, including dengue [18]. Typically fluid balance, an electrolyte supplement and blood clotting measures are used to treat the clinical symptoms of dengue [19]. In some cases, anti-D immune globulin therapy is used to treat severe thrombocytopenia [20], but because it is expensive, it can be difficult for developing and under developed countries to pay for such a treatment plan. Most residents of tropical and subtropical regions rely on herbal remedies in addition to allopathic treatment to treat dengue infection; in reality, herbal medicines have long served as useful therapeutic agents [21].

The purpose of this review is to go over the different types and structures of dengue, the transmission of dengue, the herbal treatment process and the uses of natural plant products for dengue treatment. Plants having antiviral, larvicidal, ovidical and mosquito repellent properties are also discussed.

### Types of dengue virus and structure

Dengue virus is a member of the *Flavivirus* genus and belongs to the Flaviviridae family. It is a mosquito borne human infection with the greatest rate of dissemination in the tropics. Dengue (DEN) virus has four different types of serotypes, namely DENV-1, DENV-2, DENV-3 and DENV-4 are categorized as causing a variety of symptoms, from flu-like dengue fever (DF) to dengue haemorrhagic fever (DHF), a fulminating condition that can lead to dengue shock syndrome (DSS) and finally death of patients [3,4]. At present, dengue fever, dengue haemorrhagic fever and dengue shock syndrome are considered the most significant arthropod borne viral infections and are responsible for significant morbidity and mortality [22]. Dengue virus is spherical, lipid-encapsulated viruses with a positive-strand RNA genome of around 11 kb encoding for seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5) and three structural proteins namely the envelope, membrane and capsid [23]. According to Kuhn [24], Modis [25] and Ma *et al.*, [26] non-structural proteins are involved in replication in the viral RNA of the dengue virus. The envelope protein (E) is essential for a variety of vital functions, including receptor binding, generation of a protective immunological response, blood cell hemo-agglutination, membrane fusion and virion assembly [27]. Domain I is present in the centre while domain II contains an internal fusion loop and domain II is also involved in membrane fusion and dimerization of E protein [27]. An immunoglobulin-like domain known as Domain III is hypothesized to be important in cell receptor binding. Domain II mostly comprises cross-reactive epitopes for flavivirus groups and subgroups. The seven antiparallel strands of the M-protein which is crucial for the development and maturation of the viral particle are held together by three disulphide bonds [27, 28]. The E-glycoprotein is associated with several important biological properties of dengue virus, including receptor binding, erythrocyte hemo-agglutination

and the development of neutralizing antibodies and protective immune responses [29, 30]. According to Vaughn *et al.*, [31] primary infection of dengue disease is more frequently caused by serotypes DENV-1 and DENV-3 in the south-east Asian region as compared to serotypes DENV-2 and DENV-4. Infection with a single DENV serotype produces only specific antibodies to particular serotypes. Secondary infections caused by other serotypes are more severe than primary infections if the primary infection is neutralized [32]. Although DENV-2 caused more serious and fatal infections as compared to others serotypes [33]. But some studied concludes that primary infections with DENV-1 or DENV-3 are more severe as compared to infections with serotypes DENV-2 and DENV-4 [34].




Fig 1: Structure of Dengue virus

### Sign and symptoms of dengue

The body of an *Aedes* mosquito is small and black, with white markings present on the body and legs. A female *Aedes* mosquito sucks blood from biting animal or human being to produce eggs. *Aedes aegypti* is potentially breed in stagnant water-filled containers of urban habitat [5, 35]. For further development and maturation of eggs moist environmental conditions are necessary.




Fig 2: Life cycle of *Aedes* mosquitoes

DENV is frequently spread from person to person by *Aedes* mosquitoes [33]. An outbreak begins when a mosquito feeds on the blood of a dengue fever or dengue haemorrhagic fever patient and then feeds on uninfected persons. The dengue

virus replicates in the lymph nodes and spreads in other tissues through the lymph and blood, after being spread by infected mosquitoes to a new human host [33]. The dengue virus is a small particle having an icosahedral nucleocapsid with a lipoprotein envelope and containing a single standard

positive RNA genome [33, 36]. When a virus binds to the host cell surface, infection occurs in the host cell. The receptor-mediated endocytosis process adopted by dengue virus for entering the host cell creates a sack-like structure also called an endosome [37].




Fig 3: Dengue virus transmission cycle in cell




Fig 4: Showing symptoms of dengue fever in human body

The virus enters the cell with the help of an endosome and the membrane becomes negatively charged at that point it is

combined with the membrane to provide a place for releasing genetic material in the cell. The virus in the cell now begins to

replicate. During the viral journey, variations in the acidity of the secretory pathway influence potential dengue treatment mechanisms [38]. The clinical manifestations of dengue can range from mild to severe [39]. The signs and symptoms of dengue range from a mild flu-like syndrome also called as dengue fever (DF) to the more severe conditions of the illness known as dengue haemorrhagic fever (DHF), which eventually results in dengue shock syndrome (DSS) and death of person and is characterized by coagulopathy, plasma leakage and enhancement of vascular permeability [39]. The increasing number of dengue fever (DF) patients acquiring dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) are typically a signs of dengue associated mortalities [40]. The lack of appropriate treatment exacerbates the severity of dengue [21]. The bite of female *Aedes aegypti* mosquitos carries the flavivirus to transmit dengue fever. After being bitten by a female *Aedes* mosquito, the virus incubation period ranges from 3 to 14 days [33]. The person may have earlier symptoms including headache, fever, nausea, rashes, joint and musculoskeletal pain. The period of dengue fever typically varies between five to seven days and body temperatures range between 39°C to 40°C [19, 30]. During this time the virus can enter the peripheral bloodstream and cause damage in blood vessels and lymph nodes, resulting in dengue haemorrhagic fever (DHF) conditions with symptoms like bleeding from nose, gums or under the skin if left untreated [19]. Patients with DHF also experience breathing or respiratory problems and if the condition progresses severely, it can lead to dengue shock syndrome (DSS). These conditions result in the death of a dengue patient if proper treatment is not provided [30, 41]. Dengue haemorrhagic fever, the most severe of all three types affects about 5% of all dengue patients [42]. It often lasts for 2–7 days before giving way to significant joint and muscle pain [43]. After the initial symptoms of dengue virus it causes hepatitis, organ failure, maculopathy, neurological and cardiac dysfunction, rhabdomyolysis and other consequences [44]. Dengue fever clinical manifestations are divided into three stages: the febrile period, the critical period and the recovery period. During the critical period it causes thrombocytopenia with a platelet count of less than 100,000 per mm<sup>3</sup> of normal value and induces hemo-concentration with a 20% increase in hematocrit test [45].


It primarily affects Southeast Asian children and is characterized by plasma leakage, rises vascular permeability,

thrombocytopenia and haemorrhagic manifestations. Dengue haemorrhagic and dengue shock syndrome are fatal and finally leads to death of patient [8]. There are two different types of infections caused by the dengue virus: primary and secondary [46]. A primary infection causes dengue fever (DF), which leads to an acute febrile illness that is cleared within a week by an immune response. While secondary infections are more severe and causes dengue haemorrhagic fever (DHF) or dengue shock syndrome (DSS) conditions [46].

### Transmission of dengue virus

Dengue epidemics are endemic and wider spread in more than 100 countries around the world including America, Western Pacific, Africa, Eastern Mediterranean and the Southeast Asian region [19, 47]. International traveling, rapid expansion of urban areas and increasing human populations creates favourable conditions for spread of dengue vector *Aedes aegypti* and these conditions leads to rapid expansion of dengue virus in new areas [10, 35, 37].

Human is primary vertebrates host of dengue virus. All four serotypes of dengue viruses are transmitted by *Aedes* mosquitoes of the sub genus *Stegomyia* especially *Aedes aegypti*, *Aedes albopictus* and *Aedes polynesiensis* as the primary mosquito vectors [15]. The epithelial cells of mid gut become infected after ingestion of a virus containing blood meal. The virus then penetrates the hemocoel and infects the salivary gland after escaping from the midgut epithelium. Finally, when probing, a virus is secreted in the saliva resulting in infection. A virus may penetrate the fully developed egg at the time of oviposition, because the genital tract is also infected [48]. Female *Aedes aegypti* must bite an infected individual during the viraemic phase of the disease which typically lasts 4 to 5 days but can last as long as 12 days [49]. *Aedes aegypti* can be infected with two different serotypes without compromising their yield [50]. Interrupted eating and repetitive probing of one or more hosts are characteristics of the mosquito's feeding behaviour [51]. Despite having a relatively low susceptibility to oral dengue virus infection, *Aedes aegypti* is still the most significant vector because it is highly adapted to urban habitats [52]. Because mosquito transmission is necessary for dengue virus persistence, high viral titres must grow in hosts. According to Vector Borne Viral Infection [53], the interaction between the vector and the virus may have a crucial role in the selection and spread of pathogenic dengue strains in urban areas.



**Fig 5:** Transmission of dengue from infected person to healthy person

### Herbal remedial treatment of dengue fever

Home remedies are the most effective for preventing dengue and have no side effects because they are obtained naturally. They help in treating various diseases including dengue fever and its associated symptoms [21]. According to various studies, traditional medicinal herbs and plants have antiviral and anti-dengue properties and were used to treat viral infections in both humans and animals. According to Kadir *et al.*, [21] about 30 different plant species have the potential to treat dengue fever including *Momordica charantia*, *Alternanthera philoxeroides*, *Andrographis paniculata*, *Cladosiphon okamuranus*, *Carica papaya* and *Momordica charantia* [21]. In Asian countries *Carica papaya* leaf juice is widely used as an herbal remedy against dengue fever [45]. Several studies demonstrated that *Carica papaya* leaf extract which is commonly used as a membrane stabilizing factor increases the platelet activation rate while improving the properties of white blood cells [45, 54].

*Carica papaya* also had a moderate to low inhibitory effect on dengue serotype II (DENV-2) growth *in vitro* [55]. The juice of *Carica papaya* leaves is widely used to enhance platelet counts in dengue patients [45]. The presence of various phytochemical components namely papain, phenols, flavonoids, alkaloids, ascorbic acid and saponins in *Carica papaya* leaf juice is utilized for the treatment of dengue [56]. In the Philippines, *Euphorbia hirta* is widely used to treat dengue fever by rural people [21]. It exhibits a broad range of medicinal properties, including anti-bacterial, antimalarial, antiviral, antifungal, anti-inflammatory, anti-tumor and anthelmintic [57]. Apostol *et al.*, [58] evaluated the platelet raising activity of *Euphorbia hirta* in ethanol (intra-peritoneal injection) in thrombocytopenic Sprague-Dawley rats. The results showed that 14-day administration of 100 mg/kg of *Euphorbia hirta* lyophilized decoction enhanced platelet counts in Sprague-Dawley rats [58]. The decoction of *Euphorbia hirta* reduced the bleeding time that was elevated by the intra-peritoneal injection of ethanol lowered by *Euphorbia hirta* decoction [58]. *Euphorbia hirta* treated rats show shorter clotting time as compared to ethanol-induced thrombocytopenic rats [58]. The oral treatment of *Euphorbia hirta* leaves continuously for nine days also enhanced the mean platelet count in Sprague-Dawley rats that were previously treated for 15 days with Anagrelide for the induction of thrombocytopenia [59]. In a clinical trial involving dengue patients (ages 30-55 and 14-25) admitted to the hospital Sir Ganga Ram Hospital Lahore, an oral treatment with *Euphorbia hirta* herbal water raised platelet and total leukocyte counts after 24 hours [60]. A significant platelet count increase was also found in the 30-55 age group following treatment with *Euphorbia hirta*, but no significant enhancement was found in the 14-25 age groups when compared to the 30-55 age groups [60].

The existence of nine chemicals was found during the further purification of the ethyl acetate fraction of *Euphorbia hirta* [61]. It was thought that these chemicals either alone or in combination could have contributed to anti-dengue activity [61]. *Euphorbia hirta* is also effective in raising platelet counts in dengue patients in the 30 to 55 year-old age groups [60]. Treatment with *Euphorbia hirta* significantly reduced flu-like symptoms and also exhibited anti-inflammatory properties [60, 61].

Oil of *Andropogon citratus* is used to prepare mosquito repellent candles and lanterns. Studies showed that

*Andropogon citratus* oil had mosquito repellent properties, particularly for *Aedes aegypti* [30, 62]. Turmerone extracted from *Curcuma longa* volatile oil shows mosquitocidal action against *Aedes aegypti* [30, 63]. *Piper longum* (Papal or Pippli) belongs to the Piperaceae family and its fruit, root and stem parts are used for treatment of dengue. Piperine is a substance found in *Piper longum*. Chaithong *et al.*, [64] studied the effectiveness of ethanolic extracts of *Piper ribesoides*, *Piper sarmentosum* and *Piper longum* against *Aedes aegypti*. *Piper longum* was found to be the most effective against *Aedes aegypti*, followed by *Piper sarmentosum* and *Piper ribesoides* [64]. The isolated piperonaline from *Piper longum* fruit demonstrated potent larvicidal effects on the four stages of *Aedes aegypti* larvae [65]. Female of *Stegomyia aegypti* is more susceptible to ethanol-extracted *Piper* species at different doses depending on the plant species [66]. Petroleum ether and acetone extracts of *Murraya koenigii* leaves also exhibit larvicidal activity against *Aedes aegypti* larvae [67]. Turmerone volatile oil is obtained from *Curcuma longa* and its exhibits mosquitocidal activity against *Aedes aegypti* [63]. *Eupatorium perfoliatum* is used to treat dengue fever and is taken orally as a tea [68]. The leaves and stem of *Kaempferia parviflora* are used as herbal remedies to treat viral infection [69].

According to Moon [69], the bioactive compound of *Kaempferia parviflora* directly inhibits DENV-2 virus particles. *Solanum villosum* extract has larvicidal activity against *Stegomyia aegypti* [70]. Shoot bark extracts of *Combretum collinum* show larvicidal activity against *Aedes aegypti* [71]. PON-NEEM a combined herbal formulation of *Azadirachta indica* and *Pongamia glabra* has ovicidal, larvicidal and oviposition deterrent activity against *Aedes albopictus* and *Aedes aegypti* [72]. Leaf extracts of *Eupatorium odoratum*, *Catharanthus roseus* and *Nyctanthes arbor-tristis* exhibit larvicidal activity against *Aedes aegypti* [73]. *Citrus limetta* extract had larvicidal activity against *Aedes aegypti* [74]. Leaf extract of *Acalypha alnifolia* exhibits larvicidal activity against *Aedes stephensi* and *Aedes aegypti* [75]. Seed and leaf extracts of *Delonix elata* show ovicidal and larvicidal activities against *Aedes stephensi* and *Aedes aegypti* [76]. *Ocimum sanctum* also contained phytochemicals that are mosquito repellent and larvicidal, such as farnesyl acetone, alpha-farnesene, caryophyllene and eugenol [77]. The leaf, bark and stem extracts of *Tinospora rumphii*, *Citrus grandis* and *Jatropha curcas* exhibits effective larvicidal activities. Steroids, flavonoids, tannins, saponins, flavonoids, steroid and alkaloids of *Jatropha curcas*, *Citrus grandis* and *Tinospora rumphii* are toxic to the third instar larvae of *Aedes aegypti* [78]. Tennyson *et al.*, [79] studied the ovicidal activity of three extracts, including ethyl acetate, hexane and methanol forms of the *Ageratum houstonianum* plant. They observed that all three extracts exhibit the most potent ovicidal activity at doses ranging from 2.5 to 20 mg/l [79]. Individually, chloroform, ethyl acetate, benzene, hexane and methanol chemicals were used to isolated extract from *Albizia lebbek* with the help of Soxhlet device [80].

The ovicidal effects of each extract were evaluated by measuring egg mortality and hatchability. If there is less egg hatching, then the plant extracts have stronger ovicidal activities [80]. No egg hatching results in 100% egg mortality. The majority of doses were found to be efficient at killing *Aedes* mosquito eggs [80].

According to Krishnappa and Elumalai [81], methanol extracts

of the *Aristolochia bracteata* plant exhibit impressive ovicidal activity. Leaf extracts of *Azadirachta indica* exhibit a strong effect against dengue virus, mainly serotype II<sup>[82]</sup>. The aqueous extract of *Houttuynia cordata* inhibited the replication of DENV-2 by directly inactivating viral particles prior to cell infection<sup>[32]</sup>. The leaf extract of *Hippophae rhamnoides* exhibits anti dengue activity against DENV-2<sup>[83]</sup>. According Jain *et al.*,<sup>[83]</sup> leaf extract of *Hippophae rhamnoides* improves the viability of dengue-infected cells and enhanced TNF- $\alpha$  and TNF- $\gamma$  levels. Leaf and stem extracts of *Kaempferia parviflora* exhibit virucidal activity against DENV-2.

The bioactive compound of *Kaempferia parviflora* suppresses the growth of the viral particle DENV-2<sup>[84]</sup>. Galactomannas (7), a compound extract from the seeds of *Leucaena leucocephala* has antiviral activity against DENV-1 and Yellow fever virus (YFV) *in-vivo* and *in-vitro*<sup>[9,38]</sup>. Galactomannas (7) compound isolated from seeds of *Mimosa scabrella* exhibits antiviral activity against DENV-1 and Yellow fever virus in *in-vivo* and *in-vitro* conditions<sup>[9]</sup>. Chemical compounds found in *Piper sarmentosum* include  $\alpha$ -ascarone, ascaricin,  $\beta$ -sitosterols, carotenes, xanthophyll, vitamin C and vitamin E. The ethanol extract of *Piper sarmentosum* exhibits larvicidal activity against the 4<sup>th</sup> instar larvae of *Aedes aegypti* mosquitoes<sup>[38, 85]</sup>.

*In-vitro* leaf extract of *Psidium guajava* inhibits the growth of the dengue virus<sup>[86]</sup>. Boiled leaf extract of *Psidium guajava* reduced bleeding during dengue homographic fever conditions and enhanced platelet counts to 100.000/mm<sup>3</sup> within 16 hours time<sup>[87]</sup>. An ethanolic extract of *Rhizophora apiculata* exhibits anti-dengue properties against the DENV-2 serotypes in Vero cells<sup>[88]</sup>. Some compounds extracted from *Boesenbergia rotunda* inhibited the DENV-2 dengue virus<sup>[89]</sup>. According to Muliawan *et al.*,<sup>[90]</sup> extract of *Quercus lusitanica* exhibits an inhibitory effect on the replication of DENV-2 in C6/36 cells.

## Conclusion

Dengue infection is caused by the dengue virus, which belongs to the *Flavivirus* genus and *Flaviviridae* family and is transmitted in humans through *Aedes* mosquitoes. Dengue exhibits a variety of symptoms from flu-like dengue fever to dengue haemorrhagic fever and dengue shock syndrome. During dengue fever, patients suffer from headache, fever, nausea, rash and joint and musculoskeletal pain. After the initial symptoms of dengue virus, it causes hepatitis, organ failure, maculopathy, neurological and cardiac dysfunction, rhabdomyolysis and other consequences<sup>[44]</sup>.

Extracts from various parts of plants, including leaves, fruits, bark and stems are utilized in the treatment of various diseases including dengue-related problems. The phytochemical composition of plant species exhibits various activities like larvicidal, ovicidal, virucidal and mosquitocidal effects against dengue virus and its vector and some plant compounds also exhibit mosquito repellent properties. The use of natural remedies and plant-based products increased immunity to viral diseases such as dengue.

## References

- Whitehorn J, Simmons CP. The pathogenesis of dengue. *Vaccine*. 2011;29(42):7221-7228.
- Gubler DJ. Dengue and dengue hemorrhagic fever. *Clinical Microbiology Reviews*. 1998;11(3):480-496.

- Henchal EA, Putnak RJ. The dengue viruses. *Clinical Microbiology Reviews*. 1990;3(4):376-396.
- Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. *Trends Microbiol*. 2002;10(2):100-103.
- Meena AR, Choudhary NL. Seasonal Prevalence of *Aedes aegypti* in Urban and Industrial Areas of Udaipur District, Rajasthan. *Indian Journal of Natural Sciences*. 2021;12(68):33917-33922.
- Stanaway JD, Shepard DS, Undurraga EA, Yara AH-DDS, Coffeng LE, Oliver J, *et al.* The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. *The Lancet Infectious Diseases*. 2016;16(6):712-723.
- Shepard DS, Undurraga EA, Halasa YA. Economic and Disease Burden of Dengue in Southeast Asia, *PLOS Neglected Tropical Diseases*. 2013;7(2):2055.
- WHO. Dengue: Guidelines for diagnosis, treatment, prevention and control-New edition. A joint publication of the World Health Organization (WHO) and the Special Programme for Research and Training in Tropical Diseases (TDR) WHO Library Cataloguing-in-Publication Data. Geneva, Switzerland. ISBN 978 92 4 154787 (ncbi.nlm.nih.gov/books/NBK143157/pdf/Bookshelf\_NBK143157.pdf); c2009.
- Ono L, Wollinger W, Rocco IM, Coimbra TLM, Gorin PAJ, Sierakowski MR. *In vitro* and *in vivo* antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). *Antivir Res*. 2003;60(3):201-208.
- Gubler JD. Dengue/dengue haemorrhagic fever: history and current status. In: Bock G, Goode J (eds) *New treatment strategies for dengue and other flaviviral diseases*. Wiley, Chichester (Novartis Foundation Symposium). 2006; 277:3-22.
- Durbin AP, Whitehead SS. Next-generation dengue vaccines: Novel strategies currently under development. *Viruses*. 2011;3(10):1800-1814.
- Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, *et al.* Safety and immunogenicity of a tetra-valent live-attenuated dengue vaccine in flavivirus-naïve infants. *Am. J Trop. Med. Hyg*. 2011;85(2):341-351.
- Maves RC, Ore RM, Porter KR, Kochel TJ. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in *Aotus nancymae* monkeys. *Vaccine*. 2011;29(15):2691-2696.
- Azrvedo AS, Yamamura AM, Freire MS, Trindade GF, Bonaldo M, Galler R, *et al.* DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain 3. *PLoS One*. 2011;6(7):20528.
- Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. *The New England Journal of Medicine*. 2010;366(15):1423-1432.
- Malabadi RB, Vijay Kumar S. Evaluation of antifungal property of medicinal plants. *Journal of Phytological Research*. 2008;21(1):139-142
- Singh PK, Rawat P. Evolving herbal formulations in management of dengue fever. *J Ayurveda Integr Med*. 2017;8(3):207-210.
- Rothan HA, Zulqarnain M, Ammar YA, Tan EC, Rahman NA, Yusof R. Screening of antiviral activities in medicinal plants extracts against dengue virus using

- dengue NS2B-NS3 protease assay. *Trop. Biomed.* 2014;31(2):286-96.
19. NaTHNa C. Dengue Fever. Health Protection Agency, Natural Travel Health Network and Centre, 2009, Dengue Fever. Health Protection Agency. Natural Travel Health Network and Centre; c2009.
  20. De-Castro RAC, De Castro JAA, Barez MYC, Frias MV, Dixit J, Genereux M. Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous administration of anti-D (RH0-D) immune globulin. *The American Journal of Tropical Medicine and Hygiene.* 2007;76(4):737-742.
  21. Kadir SLA, Yaakob H, Mohamed Zulkifi R. Potential anti-dengue medicinal plants: A review. *Journal of Natural Medicines.* 2013;67(4):677-689.
  22. Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. *World Health Stat Q.* 1997;50(3-4):161-168.
  23. Noble CG, Seh CC, Chao AT, Shi PY. Ligand-Bound Structures of the Dengue Virus Protease Reveal the Active Conformation. *J. Virol.* 2012;86(1):438-446.
  24. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, *et al.* Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. *Cell.* 2002;108(5):717-725.
  25. Modis Y, Ogata S, Clements D, Harrison SCA. Ligand Binding Pocket in the Dengue Virus Envelope Glycoprotein. *Proc. Natl. Acad. Sci. U.S.A.* 2003;100(12):6986-6991.
  26. Ma L, Jones CT, Groesch TD, Kuhn RJ, Post CB. Solution structure of dengue virus capsid protein reveals another fold. *Proc. Natl. Acad. Sci. U.S.A.* 2004;101(10):3414-3419.
  27. Chawla P, Yadav A, Chawla V. Clinical implications and treatment of dengue. *Asian Pacific Journal of Tropical Medicine.* Asian Pacific Journal of Tropical Medicine; c2014. p. 169-178.
  28. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, *et al.* Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. *J Virol.* 2008;82(13):6631-6643.
  29. Lalla JK, Ogale S, Seth S. A Review on Dengue and Treatments Research and reviews: journal of pharmacology and toxicological studies. 2014;2(4):13-24.
  30. Saraf M, Kavimandan B. Dengue Fever: Role of *Carica Papaya* L. *International Journal of Health Sciences & Research.* 2018;8(1):249-258.
  31. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, *et al.* Dengue in the early febrile phase: Viremia and antibody responses. *J Infect Dis.* 1997;176(2):322-330.
  32. Leardkamolkarn V, Srigulpanit W, Phurimsak C, Kumkate S, Himakoun L, Sripanidkulchai B. The inhibitory actions of *Houttuynia cordata* aqueous extract on Dengue virus and Dengue-infected cells. *J Food Biochem.* 2012;36(1):86-92. Doi:10.1111/j. 1745-4514.2010.00514.x
  33. Goel A, Patel DN, Lakhani KK, Agarwal SB, Agarwal A, Singla S, *et al.* Dengue fever: A dangerous foe. *J Indian Acad Clin Med.* 2004;5(3):247-258
  34. Tang LIC, Ling APK, Koh RY, Chye SM, Voon KGL. Screening of anti-dengue activity in methanolic extracts of medicinal plants. *BMC Complement Altern Med.* 2012;12(1):3.
  35. Amarasighe A, Kuritsky JN, Letson GW, Margolis HS. Dengue virus infection in Africa. *Emerg Infect Dis.* 2011;17(8):1349-1354
  36. Ocazionez RE, Meneses R, Torres FA, Stashenko E. Virucidal activity of Colombian Lippia essential oils on Dengue virus replication *in vitro*. *Mem Inst Oswaldo Cruz.* 2010; 105(3):304-309.
  37. Qi RF, Zhang L, Chi CW. Biological characteristics of dengue virus and potential targets for drug design. *Acta Biochim Biophys Sin.* 2008;40(2):91-101.
  38. Sarangi MK, Padh S. Dengue and its phytotherapy: A Review. *International Journal of Pharmaceutical and Phytopharmacological Research.* 2014;4(1):37-46.
  39. Martina, BEE, Koraka P, Osterhaus ADME. Dengue virus pathogenesis: an integrated view. *Clinical Microbiology Reviews.* 2009; 22(4):564-581.
  40. Guha-Sapir D, Schimmer B. Dengue fever: new paradigms for a changing epidemiology, *Emerging Temes in Epidemiology.* 2005;2(1):1.
  41. Behram MRM, Christoph N, Veaceslav B, Christian DK. The Medicinal Chemistry of Dengue Virus. *Journal of Medicinal Chemistry.* 2015;59(12):5622-5649.
  42. Rodriguez-Roche R, Gould EA. Understanding the dengue viruses and progress towards their control. *Biomed Res Int,* 2013, 690835.
  43. Jain SK. Molecular mechanism of pathogenesis of dengue virus: Entry and fusion with target cell. *Indian J Clin Biochem.* 2005;20(2):92-103.
  44. Hapugaswatta H, Amarasena P, Premaratna R, Seneviratne KN, Jayathilaka N. Differential expression of selected microRNA and putative target genes in peripheral blood cells as early markers of severe forms of dengue. *Med Rxiv;* c2019. p. 19002725.
  45. Subenthiran S, Choon TC, Cheong KC, Thayan R, Teck MB, Muniandy PK, *et al.* *Carica papaya* leaves juice significantly accelerates the rate of increase in platelet count among patients with dengue fever and dengue haemorrhagic fever. *Evidence-Based Complementary and Alternative Medicine;* c2013. p. 616737. <https://doi.org/10.1155/2013/616737>.
  46. Guzman MG, Kouri G. Dengue diagnosis, advances and challenges. *Int J Infect Dis.* 2004;8(2):69-80.
  47. Grzybowski A, Tiboni M, da Silva MAN, Chitolina RF, Passos M, Fontana JD. The combined action of phytolavacides for the control of dengue fever vector-*Aedes aegypti*. *Braz J Pharmacogn.* 2011; 22:549-557.
  48. Wolff K, Johnson RA. Viral infections of skin and mucosa. *Fitzpatrick's color atlas and synopsis of clinical dermatology.* 6th ed. New York: McGraw-Hill Medical; c2009.
  49. Knoop KJ, Stack LB, Storrow A, Thurman RJ. Tropical medicine. Atlas of emergency medicine. 3rd ed. New York: McGraw-Hill Professional; c2010.
  50. Gould EA, Solomon T. Pathogenic flaviviruses. *Lancet.* 2008;371(9611):500-509.
  51. Pongsumpun P, Tang IM. Effect of the seasonal variation in the extrinsic incubation period on the long term behavior of the dengue hemorrhagic fever. *Epidemic International J Biological Life Sci.* 2007;3(3):208-214.
  52. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J,

- Gubler DJ, *et al.* Dengue: a continuing global threat. *Nat Rev Microbiol.* 2010;8(12):7-16.
53. Vector-borne viral infections. World Health Organization. [Online] Available from: [http://www.who.int/vaccine\\_research/documents/Vector\\_Borne\\_Viral\\_Infections](http://www.who.int/vaccine_research/documents/Vector_Borne_Viral_Infections). [Accessed on Jan 2013]; c2013.
  54. Jayasinghe CD, Gunasekera DS, De Silva N, Jayawardena KKM, Udagama PV. Mature leaf concentrate of Sri Lankan wild type *Carica papaya* Linn. Modulates non-functional and functional immune responses of rats. *BMC Complementary and Alternative Medicine.* 2017;17(1):230.
  55. Joseph B, Sankarganesh P, Ichiyama K, Yamamoto N. *In vitro* study on cytotoxic effect and anti-DENV2 activity of *Carica papaya* L. leaf. *Frontiers in Life Science.* 2015;8(1):18-22.
  56. Subramanian G, Tewari BB, Gomathinayagam R. Antimicrobial properties of *Carica papaya* (Papaya) different leaf extract against *E. coli*, *S. aureus* and *C. albicans*. *Adv J Pharmacol Pharmacother.* 2014; 1:25-39.
  57. Kumar S, Malhotra R, Kumar D. *Euphorbia hirta*: Its chemistry, traditional and medicinal uses, and pharmacological activities. *Pharmacognosy Reviews.* 2010;4(7):58-61.
  58. Apostol JG, Gan JV, Raynes RJ, Sabado AA, Carigma AQ, Santiago LA. Platelet-increasing effects of *Euphorbia hirta* Linn. (Euphorbiaceae) in ethanol-induced thrombocytopenic rat models. *International Journal of Pharmaceutical Frontier Research.* 2012;2(2):1-11.
  59. Arollado EC, Pena IG, Dahilig VR. Platelet augmentation activity of selected Philippine plants. *International Journal of Pharmaceutical Frontier Research.* 2014;3(2):121-123.
  60. Mir M, Khurshid R, Afaab R. Management of thrombocytopenia and flu-like symptoms in dengue patients with herbal water of *Euphorbia hirta*. *Journal of Ayub Medical College.* 2012; 24(3-4):6-9.
  61. Tayone WC, Tayone JC, Hashimoto M. Isolation and structure elucidation of potential Anti-Dengue metabolites from Tawa-Tawa (*Euphorbia hirta* Linn.). *Walailak Journal of Science and Technology.* 2014;11(10):825-832.
  62. Gadhwal AK, Ankit BS, Chahar C, Tantia P, Sirohi P, Agrawal RP. Effect of *Carica papaya* Leaf Extract Capsule on Platelet Count in Patients of Dengue Fever with Thrombocytopenia. *Journal of association of physicians in India.* 2016;64(6):22-26.
  63. Roth GN, Chandra A, Nair MG. Novel bioactivities of *Curcuma longa* constituents. *Journal of Natural Products.* 1998;61(4):542-545.
  64. Chaithong U, Choochote W, Kamsuk K, Jitpakdi A, Tippawangkosol P, Chaiyasit D, *et al.* Larvicidal effect of pepper plants on *Aedes aegypti*. *Journal of Vector Ecology.* 2006;31(1):138-144.
  65. Govindarajan MA, Jebanesan, Pushpanathan T, Samidurai K. Studies on effect of *Acalypha indica* L. (Euphorbiaceae) leaf extracts on the malarial vector, *Anopheles stephensi* Liston (Diptera: Culicidae). *Parasitol. Res.* 2008;103(3):691-695.
  66. Wej-choochote, Chaithong U, Kamsuk K, Rattanachanpichai E, Jitpakdi A, Tippawangkosol P, *et al.* Adulticidal activity against *Stegomyia. aegypti* (Diptera: culicidae) of three piper spp. *Rev. Inst. Med. trop. S. Paulo.* 2006;48(1):33-37.
  67. Harve G, Kamath V. Larvicidal activity of plant extracts used alone and in combination with known synthetic larvicidal agents against *Aedes aegypti*. *Ind. J. Exp. Biol.* 2004;42(12):1216-1219.
  68. Innvista.com. Boneset. [Online] Available from: <http://www.innvista.com/health/herbs/boneset.htm> [Accessed on Jan 2013]; c2013.
  69. Moon HI, Cho SB, Lee JH, Paik HD, Kim SK. Immunotoxicity activity of sesquiterpenoids from black galingale (*Kaempferia parviflora* Wall. Ex. Baker) against *Aedes aegypti* L. *Immunopharmacol Immunotoxicol.* 2011;33(2):380-383.
  70. Chowdhury N, Ghosh A, Chandra G. Mosquito larvicidal activities of *Solanum villosum* berry extract against the dengue vector *Stegomyia aegypti*. *BMC Complement Altern Med.* 2008;8(1):1-0. Doi: 10.1186/1472-6882-8-10.
  71. Odda J, Kristensen S, Kabasa J, Waako P. Larvicidal activity of *Combretum collinum* Fresen against *Aedes aegypti*. *J Vector Borne Dis.* 2008; 45:321-324.
  72. Maheswaran R, Ignacimuthu S. A novel herbal formulation against dengue vector mosquitoes *Aedes aegypti* and *Aedes albopictus*. *Parasitol Res.* 2012;110(5):1801-1813.
  73. Alam MF, Safhi MM, Chopra AK, Dua VK. Toxicological properties of several medicinal plants from the Himalayas (India) against vectors of malaria, filariasis and dengue. *Trop Biomed.* 2011;28(2):343-350.
  74. Kumar S, Rehman I, Dhyani P, Kumari L, Acharya S. Molecular herbal inhibitors of dengue virus, an update. *International Journal of Medicinal and Aromatic plants.* 2012;2(1):1-21.
  75. Kovendan K, Murugan K, Kumar AN, Vincent S, Hwang JS. Bio efficacy of larvicidal and pupicidal properties of *Carica papaya* (Caricaceae) leaf extract and bacterial insecticide, spinosad, against chikungunya vector, *Aedes aegypti* (Diptera: Culicidae). *Parasitol Res.* 2012;110(2):669-78.
  76. Marimuthu G, Rajamohan S, Mohan R, Krishnamoorthy Y. Larvicidal and ovicidal properties of leaf and seed extracts of *Delonix elata* (L.) Gamble (family: Fabaceae) against malaria (*Anopheles stephensi* Liston) and dengue (*Aedes aegypti* Linn.) (Diptera: Culicidae) vector mosquitoes. *Parasitol Res.* 2012;111(1):65-77.
  77. Shazad M, Gupta KK, Kayesth S, Kumar S. Sub lethal effects of ethanol extract of *Ocimum sanctum* on laboratory-bred population of dengue mosquito *Aedes aegypti* L. (Diptera: Culicidae). *Vector Biol J.* 2018; 3:1-7.
  78. Gutierrez PM, Antepuesto AN, Eugenio BA, Santos MF. Larvicidal activity of selected plant extracts against the dengue vector *Aedes aegypti* mosquito. *Int Res J Biol Sci.* 2014;3(4):23-32.
  79. Tennyson S, Ravindran KJ, Eapen A, William SJ. Ovicidal activity of *Ageratum houstonianum* Mill. (Asteraceae) leaf extracts against *Anopheles stephensi*, *Aedes aegypti* and *Culex quinquefasciatus* (Diptera: Culicidae). *Asian Pac J Trop Med.* 2015;5(3):199-203.
  80. Govindarajan M, Rajeswary M. Ovicidal and adulticidal potential of leaf and seed extract of *Albizia lebbbeck* (L.) Benth. (Family: Fabaceae) against *Culex*



- quinquefasciatus*, *Aedes aegypti* and *Anopheles stephensi* (Diptera: Culicidae). Parasitology Res. 2015;114(5):1949-1961.
81. Krishnappa K, Elumalai K. Toxicity of *Aristolochia bracteata* methanol leaf extract against selected medically important vector mosquitoes (Diptera: Culicidae). Asian Pac J Trop Med. 2012; 2:553-557.
  82. Parida MM, Upadhyay C, Pandya G, Jana AM. Inhibitory potential of neem (*Azadirachta indica* Juss) leaves on Dengue virus type-2 replication. J Ethnopharmacol. 2002;79(2):273-278.
  83. Jain M, Ganju L, Katiyal A, Padwad Y, Mishra KP, Chanda S, Karan D, Yogendra KMS, Sawhney RC. Effect of *Hippophae rhamnoides* leaf extracts against Dengue virus infection in human blood-derived macrophages. Phytomedicine. 2008;15(10):793-799.
  84. Phurimsak C, Leardkamolkarn V. Screening for antiviral effect of Thai herbs; *Kaempferia parviflora*, *Ellipeiopsis cherrevensis* and *Stemona tuberosa* against dengue virus type-2. 31st congress on science and technology of Thailand. Suranaree University of Technology; c2005.
  85. Udom C, Wej C, Kittichai K, Jitpakdi A, Tippawangkosol P, Chaiyasit D, et al. Larvicidal effect of pepper plants on *Aedes aegypti* (L.) (Diptera: Culicidae). Journal of Vector Ecology. 2006;31(1):138-144.
  86. Pink Roses. Guava leaf extracts potential cure dengue fever. <http://pinkroses.info/guava-leaf-extract-potential-cure-dengue-fever>; c2011.
  87. Healthy Lifestyle. Guava leaf, prevent Dengue Haemorrhage. <http://www.secondlifeblogs.info/guava-leafprevent-denguehaemorrhage.html>; c2010.
  88. Klawikkan N, Nukoolkarn V, Jirakanjanakir N, Yoksan S, Wiwat C, Thirapanmethee K. Effect of Thai medicinal plant extracts against Dengue virus *in vitro*. Mahidol University Journal of Pharmaceutical Science. 2011;38(1-2):13-18.
  89. Kiat TS, Phippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of finger root, *Boesenbergia rotunda* (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett. 2006; 16(12):3337-3340.
  90. Muliawan SY, Kit LS, Devi S, Hashim O, Yusof R. Inhibitory potential of *Quercus lusitanica* extract on Dengue virus type 2 replication. Southeast Asian J Trop Med Public Health. 2006; 37(9):132-135.